PRJNA770630
Ewing sarcoma A673 cells, TK216-resistant clones
TK216 is in phase II clinical trials for the treatment of Ewing sarcoma, although the mechanism of action in cells is still unknown. These samples are from a forward genetic screening using MMR-deficient A673 cells to identify the mechanism of action of TK216 in cells.